Belpointe Asset Management LLC Purchases Shares of 149 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Belpointe Asset Management LLC purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 149 shares of the medical research company’s stock, valued at approximately $63,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Mather Group LLC. increased its holdings in shares of Bio-Rad Laboratories by 6.8% during the first quarter. Mather Group LLC. now owns 377 shares of the medical research company’s stock valued at $212,000 after acquiring an additional 24 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Bio-Rad Laboratories by 1.7% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 1,483 shares of the medical research company’s stock valued at $624,000 after acquiring an additional 25 shares in the last quarter. Raymond James Trust N.A. increased its holdings in shares of Bio-Rad Laboratories by 5.5% during the first quarter. Raymond James Trust N.A. now owns 501 shares of the medical research company’s stock valued at $283,000 after acquiring an additional 26 shares in the last quarter. Advisors Asset Management Inc. increased its holdings in shares of Bio-Rad Laboratories by 0.7% during the third quarter. Advisors Asset Management Inc. now owns 3,637 shares of the medical research company’s stock valued at $1,517,000 after acquiring an additional 27 shares in the last quarter. Finally, Texas Permanent School Fund grew its holdings in Bio-Rad Laboratories by 0.9% during the fourth quarter. Texas Permanent School Fund now owns 3,059 shares of the medical research company’s stock worth $1,286,000 after buying an additional 27 shares in the last quarter. Institutional investors own 64.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. StockNews.com assumed coverage on Bio-Rad Laboratories in a report on Thursday. They set a “buy” rating for the company. Credit Suisse Group upped their price objective on Bio-Rad Laboratories from $640.00 to $680.00 and gave the company an “outperform” rating in a research note on Friday, February 17th. Royal Bank of Canada upped their price objective on Bio-Rad Laboratories from $571.00 to $579.00 and gave the company an “outperform” rating in a research note on Friday, February 17th. Finally, TheStreet upgraded Bio-Rad Laboratories from a “d+” rating to a “c” rating in a research note on Thursday, February 16th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $653.00.

Bio-Rad Laboratories Stock Up 0.5 %

Shares of NYSE BIO opened at $382.14 on Monday. Bio-Rad Laboratories, Inc. has a one year low of $344.63 and a one year high of $572.70. The company has a debt-to-equity ratio of 0.12, a current ratio of 5.56 and a quick ratio of 4.28. The business’s fifty day moving average price is $447.80 and its 200-day moving average price is $442.37. The stock has a market capitalization of $11.32 billion, a PE ratio of -58.43 and a beta of 0.91.

Bio-Rad Laboratories (NYSE:BIO – Get Rating) last issued its quarterly earnings results on Thursday, May 4th. The medical research company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.24 by $0.10. Bio-Rad Laboratories had a positive return on equity of 4.10% and a negative net margin of 7.01%. The firm had revenue of $676.80 million for the quarter, compared to analysts’ expectations of $689.28 million. During the same quarter in the prior year, the firm earned $4.94 EPS. The business’s revenue for the quarter was down 3.3% compared to the same quarter last year. On average, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 14.55 EPS for the current year.

Insider Buying and Selling

In related news, EVP Timothy S. Ernst sold 1,746 shares of the stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $486.43, for a total transaction of $849,306.78. Following the sale, the executive vice president now owns 2,671 shares of the company’s stock, valued at approximately $1,299,254.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 17.06% of the stock is currently owned by insiders.

About Bio-Rad Laboratories

(Get Rating)

Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.